Lodenosine
Alternative Names: 2'-F-dd-ara-A; 2'-Fluoro-2',3'-dideoxyarabinosyladenine; DDG 1; FddA; Fddl; NSC 613792Latest Information Update: 11 Jan 2001
Price :
$50 *
At a glance
- Originator National Cancer Institute (USA); National Institutes of Health (USA)
- Developer MedImmune Oncology; National Institutes of Health (USA)
- Class Antiretrovirals; Dideoxynucleosides; Small molecules
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 11 Jan 2001 Discontinued-II for HIV infections treatment in Brazil (PO)
- 11 Jan 2001 Discontinued-II for HIV infections treatment in United Kingdom (PO)
- 11 Jan 2001 Discontinued-II for HIV infections treatment in USA (PO)